This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as a Hybrid Event from September 20-30, 2021
Live Digital Agenda Runs 11am-3pm EST from Sept 28-30Boston Convention and Exhibition Center

Joe Makowiecki
Director of Business Development, Enterprise Solutions at Cytiva

Profile

Joe has been in the Bioprocess industry for 26 years and has held management, senior management and director positions within Process Development, Pilot Plant, cGMP Manufacturing and Enterprise Solutions organizations. As Cytiva’s Director of Business Development for Enterprise Solutions, his responsibilities include product management of the FlexFactory (single-use, flexible and deployable biomanufacturing platforms), strategy for both the FlexFactory and KUBio (modular facility solutions) offerings, new technology identification and integration and commercial activation.
Joe also heads up the Technology, Consumables & Commercial Activation Team (TCCAT). TCCAT is made up of several end-to-end bioprocess SMEs that focus on cell culture & fermentation, chromatography, filtration, single use consumables and new biomanufacturing technologies. The objective of the team is to lead/drive/support the strategy, design, expansion, evolution and commercial activation of Cytiva’s Enterprise Solutions & Single Use offerings through navigation, communication and collaboration with internal stakeholders, and external partners.  
Joe’s expertise and experience includes downstream process development, scale up, cGMP manufacturing, process technical transfer, manufacturing site operations, contract manufacturing services, bioprocess solution selling and business development. He has been involved with the development, technical transfer, scale-up and manufacture of multiple diagnostic, vaccine and bio therapeutic products from mammalian, microbial and insect expression systems.

Agenda Sessions

  • ROOM 258AB: Flexible approaches to addressing mRNA vaccine demand

    11:30am